Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
1d
Barchart on MSNGilead Sciences - Leader in HIV MedicinesYour FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
3d
News-Medical.Net on MSNGilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIVGilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results